[Leslie Carol Botha: Another vaccine aimed at women. Although we may fear breast cancer… injecting toxins into our breast tissue should frighten women even more. Where will these toxins be stored? How will this affect breastfeeding? Will these toxins directly go into breast milk? And then there is the whole issue of puncturing a potential tumor and sending the cancerous cells further into the breast, bloodstream or lymph nodes. And remember, vaccines are given to women without regard to wear they are in the menstrual cycle. If you choose this type of breast prevention – please do not get vaccinated when you are premenstrual or having your period. This is the absolutely the time when your immune system is most compromised. The government knows this. The study on immunity and the menstrual cycle is posted on their web site.]
Breast cancer vaccine shows promise in study
By Todd Ackerman
Wednesday, May 16, 2012
Houston researchers on Wednesday reported positive results with an experimental breast cancer vaccine, a promising development in an emerging field in cancer care.
The vaccine, one of many now in testing, significantly decreased the recurrence rate of breast cancer in women who had been treated for a common tumor type, according to a study led by the University of Texas M.D. Anderson Cancer Center.
“If this vaccine and others continue to perform well in trials, they could change practice standards in breast cancer,” said Dr. Elizabeth Mittendorf, an M.D. Anderson surgical oncology professor and the study’s principal investigator.
Mittendorf said cancer researchers are in “the dawn of a new era,” in which scientists are learning to manipulate the immune system to recognize cancer cells and prevent or treat the disease. She said vaccines for breast cancer have lagged behind those for other cancer types but are starting to catch up.
The new vaccine triggers the patient’s immunity against a tumor protein, known as HER2, present to some extent in 75 percent to 80 percent of breast cancers.
It is best known when it occurs in high levels – HER2-positive breast cancers – but it occurs in lower levels in more than half of other breast cancers, plus a number of other cancers, such as prostate, ovarian and gastric cancers. This suggests the drug could provide benefits for patients with these cancers in addition to those with breast cancer.
The vaccine reduced breast cancer recurrence in women who had both high and low levels of HER2.